MCID: BPL003
MIFTS: 61

Bipolar Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Bipolar Disorder

MalaCards integrated aliases for Bipolar Disorder:

Name: Bipolar Disorder 39 12 77 54 26 38 56 44 45 15 17 74
Major Affective Disorder 54 41 74
Bipolar Affective Disorder 54 26
Depression, Bipolar 26 74
Bipolar Depression 12 15
Manic Depression 12 54
Manic Disorder 12 74
Manic Bipolar Affective Disorder 12
Bipolar Disorder Manic Phase 12
Bipolar Affective Psychosis 26
Major Affective Disorder 1 74
Manic-Depressive Psychosis 54
Major Affective Disorder 2 74
Manic Depressive Disorder 12
Bipolar Spectrum Disorder 26
Manic Bipolar I Disorder 12
Manic Depressive Illness 26
Affective Disorder Major 56
Depressive-Manic Psych. 12
Bipolar Disorder, Mixed 74
Mixed Bipolar Disorder 12
Depression Bipolar 56
Bipolar Illness 54

Classifications:



Summaries for Bipolar Disorder

MedlinePlus : 44 Bipolar disorder is a serious mental illness. People who have it go through unusual mood changes. They go from very happy, "up," and active to very sad and hopeless, "down," and inactive, and then back again. They often have normal moods in between. The up feeling is called mania. The down feeling is depression. The causes of bipolar disorder aren't always clear. It runs in families. Abnormal brain structure and function may also play a role. Bipolar disorder often starts in a person's late teen or early adult years. But children and adults can have bipolar disorder too. The illness usually lasts a lifetime. If you think you may have it, tell your health care provider. A medical checkup can rule out other illnesses that might cause your mood changes. If not treated, bipolar disorder can lead to damaged relationships, poor job or school performance, and even suicide. However, there are effective treatments to control symptoms: medicine and talk therapy. A combination usually works best. NIH: National Institute of Mental Health

MalaCards based summary : Bipolar Disorder, also known as major affective disorder, is related to major depressive disorder and bipolar i disorder. An important gene associated with Bipolar Disorder is DAOA-AS1 (DAOA Antisense RNA 1), and among its related pathways/superpathways is Neurotransmitter Clearance In The Synaptic Cleft. The drugs Lamotrigine and Ziprasidone have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A mood disorder that involves alternating periods of mania and depression.

Genetics Home Reference : 26 Bipolar disorder is a mental health condition that causes extreme shifts in mood, energy, and behavior. This disorder most often appears in late adolescence or early adulthood, although symptoms can begin at any time of life.

NIH Rare Diseases : 54 Bipolar disorder is a type of mental illness that causes unusual shifts in mood, energy, activity levels, sleep and behavior. Signs and symptoms typically include alternating periods of manic episodes (joyful or excited states) and depressive episodes (very sad, hopeless or empty states). Mood episodes may also include symptoms of both mania and depression (a mixed state). It often develops in the late teens or early adult years, but age of onset can range from childhood to late in life. Bipolar disorder can run in families, although no single gene is thought to cause the condition. Many factors acting together likely increase a person's risk to develop the disorder. Treatment may include medication and psychotherapy for preventing relapses and reducing the severity of symptoms.

Wikipedia : 77 Bipolar disorder, previously known as manic depression, is a mental disorder that causes periods of... more...

Related Diseases for Bipolar Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 384)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 33.3 BDNF COMT DISC1 DISC2 DRD3 SLC6A4
2 bipolar i disorder 33.2 BDNF COMT SLC6A4
3 schizoaffective disorder 33.2 BDNF COMT DAOA DISC1 DISC2 DRD3
4 depression 33.1 BDNF DISC2 RELN SLC6A4
5 schizophrenia 33.1 ATP2A2 BDNF COMT DAOA DAOA-AS1 DISC1
6 psychotic disorder 33.1 BDNF COMT DAOA DISC1 DRD3 RELN
7 mood disorder 32.9 BDNF COMT DAOA DISC1 DISC2 DRD3
8 migraine with or without aura 1 32.9 COMT DRD3 SLC6A4
9 schizophrenia 2 32.2 DISC1 DISC2 DRD3
10 mental depression 32.1 BDNF COMT SLC6A4
11 anxiety 32.1 BDNF COMT SLC6A4
12 personality disorder 32.0 BDNF COMT SLC6A4
13 borderline personality disorder 32.0 BDNF COMT SLC6A4
14 obsessive-compulsive disorder 31.8 BDNF COMT DRD3 SLC6A4
15 attention deficit-hyperactivity disorder 31.8 BDNF COMT DRD3 SLC6A4
16 substance abuse 31.8 BDNF COMT DRD3 SLC6A4
17 alcohol dependence 31.7 BDNF COMT DRD3 SLC6A4
18 disease of mental health 31.7 BDNF COMT DISC1 DRD3 RELN SLC6A4
19 eating disorder 31.5 BDNF COMT SLC6A4
20 substance dependence 31.3 BDNF DRD3 SLC6A4
21 alcohol abuse 31.3 BDNF DRD3 SLC6A4
22 post-traumatic stress disorder 31.2 BDNF COMT SLC6A4
23 panic disorder 31.2 COMT DAOA-AS1 SLC6A4
24 paranoid schizophrenia 31.2 BDNF COMT SLC6A4
25 postpartum depression 31.0 BDNF COMT SLC6A4
26 generalized anxiety disorder 31.0 BDNF COMT SLC6A4
27 pervasive developmental disorder 30.9 BDNF RELN SLC6A4
28 tardive dyskinesia 30.9 COMT DRD3
29 autism spectrum disorder 30.9 BDNF DISC2 RELN SLC6A4
30 anorexia nervosa 30.7 BDNF COMT SLC6A4
31 alexithymia 30.6 COMT SLC6A4
32 oppositional defiant disorder 30.5 COMT SLC6A4
33 fibromyalgia 30.5 COMT SLC6A4
34 bulimia nervosa 30.5 BDNF COMT SLC6A4
35 traumatic brain injury 30.5 BDNF COMT
36 parkinson disease, late-onset 30.4 BDNF COMT DRD3 SLC6A4
37 pathological gambling 30.3 DRD3 SLC6A4
38 major affective disorder 3 11.5
39 major affective disorder 7 11.5
40 major affective disorder 1 11.5
41 major affective disorder 8 11.5
42 major affective disorder 9 11.5
43 cyclothymic disorder 11.3
44 schizophrenia 9 11.3
45 major affective disorder 2 11.2
46 major affective disorder 4 11.2
47 major affective disorder 5 11.2
48 major affective disorder 6 11.2
49 valproate embryopathy 11.1
50 darier-white disease 11.0

Comorbidity relations with Bipolar Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypertension, Essential Hypothyroidism
Major Affective Disorder 9 Major Depressive Disorder
Parkinson Disease, Late-Onset Schizophrenia
Schizophreniform Disorder Tardive Dyskinesia

Graphical network of the top 20 diseases related to Bipolar Disorder:



Diseases related to Bipolar Disorder

Symptoms & Phenotypes for Bipolar Disorder

GenomeRNAi Phenotypes related to Bipolar Disorder according to GeneCards Suite gene sharing:

27 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.64 IMPA2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.64 IMPA2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.64 DRD3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.64 DRD3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.64 ATP2A2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.64 DRD3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.64 DRD3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.64 DRD3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.64 ATP2A2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.64 ATP2A2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.64 ATP2A2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.64 IMPA2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.64 ATP2A2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.64 ATP2A2 DRD3 IMPA2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.64 ATP2A2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.64 DRD3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.64 DRD3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.64 IMPA2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.64 DRD3
20 Decreased DCP1a protein expression and assembly in processing bodies after arsenite stimulation GR00203-A 9.13 DRD3 RELN SLC6A4

Drugs & Therapeutics for Bipolar Disorder

Drugs for Bipolar Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 505)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
2
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
3
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2
4
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99-66-1 3121
5
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
6
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 54910-89-3 3386
7
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 106266-06-2 5073
8
Sertraline Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79617-96-2 68617
9
Topiramate Approved Phase 4,Phase 3,Phase 1 97240-79-4 5284627
10
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
11
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 132539-06-1 4585
12
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 298-46-4 2554
13
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 616-91-1 12035
14
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
15
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
16
Coal tar Approved Phase 4,Phase 2 8007-45-2
17
Bupropion Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 34841-39-9, 34911-55-2 444
18
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
19
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
20
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 61869-08-7 43815
21
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
22
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
23
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-41-2 439260
24
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6740-88-1 3821
25
Midazolam Approved, Illicit Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable 59467-70-8 4192
26
Pramipexole Approved, Investigational Phase 4,Phase 2 104632-26-0 119570 59868
27
tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 1401-55-4
28
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
29
Varenicline Approved, Investigational Phase 4,Not Applicable 249296-44-4 5310966
30
Nortriptyline Approved Phase 4 72-69-5 4543
31
Modafinil Approved, Investigational Phase 4,Phase 2 68693-11-8 4236
32
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
33
Iloperidone Approved Phase 4,Phase 1 133454-47-4 71360
34
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-36-2 446220 5760
35
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 16590-41-3 5360515
36
Galantamine Approved Phase 4,Phase 3,Not Applicable 357-70-0 9651
37
Clozapine Approved Phase 4,Phase 3,Phase 2,Not Applicable 5786-21-0 2818
38
Ondansetron Approved Phase 4,Phase 3 99614-02-5 4595
39
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
40
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1 51-45-6 774
41
Tranylcypromine Approved, Investigational Phase 4,Not Applicable 155-09-9 441233
42
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
43
Acetylcholine Approved, Investigational Phase 4,Not Applicable 51-84-3 187
44
Acamprosate Approved, Investigational Phase 4,Phase 1,Phase 2 77337-76-9 71158
45
Cycloserine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 68-41-7 6234 401
46
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
47
Donepezil Approved Phase 4 120014-06-4 3152
48
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 10118-90-8 5281021
49
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
50
Chlorpromazine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-53-3 2726

Interventional clinical trials:

(show top 50) (show all 1342)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
2 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
3 Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
4 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
5 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
6 Efficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder Unknown status NCT02252341 Phase 4
7 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
8 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
9 Guidance Model of Standardized Treatment of Antidepressants in Bipolar Disorder Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
10 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
11 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
12 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
13 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
14 Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
15 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
16 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
17 Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness Completed NCT00545675 Phase 4 Abilify(aripiprazole);Depakote (divalproate)
18 Targeting Cognition in Bipolar Disorder With Pramipexole Completed NCT02397837 Phase 4 Pramipexole;Placebo
19 Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder Completed NCT00667745 Phase 4 Lithium Carbonate;Optimized Treatment (OPT)
20 Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder Completed NCT01010204 Phase 4 Varenicline;Placebo
21 Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder Completed NCT02456896 Phase 4 Oxcarbazepine
22 Memantine and Cognitive Dysfunction in Bipolar Disorder Completed NCT00586066 Phase 4 Memantine;Placebo
23 Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode Completed NCT02918097 Phase 4 Lithium Carbonate;Sertraline;Nortriptyline;Risperidone
24 Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder Completed NCT01864551 Phase 4 Lamotrigine;Olanzapine
25 Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil Completed NCT01965925 Phase 4 Modafinil;Placebo
26 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States. Completed NCT00154323 Phase 4 Oxcarbazepine
27 Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine Completed NCT00394095 Phase 4 Topiramate;Placebo
28 Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder Completed NCT00199966 Phase 4 Divalproex sodium extended release
29 Comparative Effectiveness Study for Bipolar Disorder Completed NCT01331304 Phase 4 Lithium;Quetiapine
30 Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness Completed NCT00545142 Phase 4 Abilify(Aripiprazole);Depakote(Divalproate)
31 Aripiprazole in Late Life Bipolar Disorder Completed NCT00194038 Phase 4 Aripiprazole
32 Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder Completed NCT00227968 Phase 4
33 Asenapine in the Treatment of Older Adults With Bipolar Disorder Completed NCT01460290 Phase 4 Asenapine
34 Ziprasidone in Pediatric Bipolar Disorder Completed NCT00622739 Phase 4 Ziprasidone;Ziprasidone
35 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
36 Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad) Completed NCT01293825 Phase 4 ziprasidone
37 Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder Completed NCT01195363 Phase 4 quetiapine SR;quetiapine sr placebo
38 Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
39 Iloperidone in Mixed States of Bipolar Disorder Completed NCT02413918 Phase 4 iloperidone
40 Cognitive Enhancement in Bipolar Disorder Completed NCT00597896 Phase 4 pramipexole
41 An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder Completed NCT00360126 Phase 4 lamotrigine
42 Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder Completed NCT00552760 Phase 4 Ramelteon;Placebo
43 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency Completed NCT00280293 Phase 4 Lamotrigine;Placebo
44 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
45 Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder Completed NCT00741598 Phase 4 Galantamine-ER;Galantamine placebo
46 Lamictal As Add on Treatment in Mixed States of Bipolar Disorder Completed NCT00223509 Phase 4 Lamotrigine
47 FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder Completed NCT00596622 Phase 4 Lithium
48 Geodon in Weight Loss Study for Bipolar Disorders Completed NCT00472641 Phase 4 Ziprasidone/Geodon
49 Valproic Acid Sodium Salt in Bipolar Disorder Completed NCT00431522 Phase 4 Valproic acid, sodium salt
50 Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Completed NCT00845988 Phase 4 aripiprazole

Search NIH Clinical Center for Bipolar Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: bipolar disorder

Genetic Tests for Bipolar Disorder

Anatomical Context for Bipolar Disorder

MalaCards organs/tissues related to Bipolar Disorder:

42
Brain, Cortex, Testes, Heart, Eye, Prefrontal Cortex, Amygdala

Publications for Bipolar Disorder

Articles related to Bipolar Disorder:

(show top 50) (show all 5628)
# Title Authors Year
1
Understanding Aging in Bipolar Disorder by Integrating Archival Clinical Research Datasets. ( 31097301 )
2019
2
The Global Aging & Geriatric Experiments in Bipolar Disorder Database (GAGE-BD) project: Understanding older-age bipolar disorder by combining multiple datasets. ( 31081573 )
2019
3
Delay discounting and reward sensitivity in a 2x2 study of bipolar disorder and alcohol dependence. ( 30927381 )
2019
4
Alexithymia predicts poorer social and everyday functioning in schizophrenia and bipolar disorder. ( 30658205 )
2019
5
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. ( 29855563 )
2019
6
Differential levels of prefrontal cortex glutamate+glutamine in adults with antisocial personality disorder and bipolar disorder: A proton magnetic resonance spectroscopy study. ( 30959086 )
2019
7
Anxiety symptoms across twenty-years in schizoaffective disorder, bipolar disorder, and major depressive disorder. ( 30953876 )
2019
8
An evaluation of the impact of co-occurring anxiety and substance use disorder on bipolar disorder illness outcomes in STEP-BD. ( 30623826 )
2019
9
The Association of Lifetime Suicide Attempts With Anxiety Disorders in Patients With Bipolar Disorder. ( 30633727 )
2019
10
Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. ( 30292023 )
2019
11
The impact of COMT polymorphisms on cognition in Bipolar Disorder: A review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. ( 30146088 )
2019
12
The impact of BDNF Val66Met polymorphism on cognition in Bipolar Disorder: A review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. ( 30078664 )
2019
13
MRI features of clinical outcome in bipolar disorder: A selected review: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. ( 29907266 )
2019
14
Risks of bipolar disorder, depressive disorder, and traumatic brain injury among siblings of patients with attention-deficit hyperactivity disorder. ( 30419534 )
2019
15
Single Quantum Dot Imaging Reveals PKCβ-Dependent Alterations in Membrane Diffusion and Clustering of an Attention-Deficit Hyperactivity Disorder/Autism/Bipolar Disorder-Associated Dopamine Transporter Variant. ( 30153408 )
2019
16
Attention deficit-hyperactivity disorder in adult bipolar disorder patients. ( 30267955 )
2019
17
Impulsivity and its association with childhood trauma experiences across bipolar disorder, attention deficit hyperactivity disorder and borderline personality disorder. ( 30336349 )
2019
18
Affective Temperament and Seasonality in Bipolar Disorder. ( 30948697 )
2019
19
Abnormal Degree Centrality Associated With Cognitive Dysfunctions in Early Bipolar Disorder. ( 30949078 )
2019
20
Attention Deficits in a Comorbidity-Free Sample of Euthymic Pediatric Bipolar Disorder. ( 30949082 )
2019
21
Increased and Decreased Superficial White Matter Structural Connectivity in Schizophrenia and Bipolar Disorder. ( 30953566 )
2019
22
Distinguishing prodromal stage of bipolar disorder and early onset schizophrenia spectrum disorders during adolescence. ( 30953877 )
2019
23
Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder. ( 30954559 )
2019
24
Higher in vivo Cortical Intracellular Volume Fraction Associated with Lithium Therapy in Bipolar Disorder: A Multicenter NODDI Study. ( 30955011 )
2019
25
Financial difficulties in bipolar disorder part 2: psychological correlates and a proposed psychological model. ( 30955385 )
2019
26
Correction to: Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial. ( 30961672 )
2019
27
Neural Markers That Distinguish Bipolar Disorder From Major Depressive Disorder: Moving Closer to a Reality. ( 30961832 )
2019
28
Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review. ( 30963507 )
2019
29
Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder. ( 30966917 )
2019
30
Peripheral blood lymphocyte subpopulations in patients with bipolar disorder type II. ( 30971748 )
2019
31
Risk of Posttraumatic Stress Disorder and Its Relationship With Perceived Social Support Among Family Caregivers of Individuals With Schizophrenia or Bipolar Disorder. ( 30973614 )
2019
32
The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression. ( 30974123 )
2019
33
Work motivation in patients with bipolar disorder: Associated factors. ( 30977426 )
2019
34
Psychological interventions for young people at risk for bipolar disorder: A systematic review. ( 30981060 )
2019
35
Symptoms, course of Illness, and comorbidity as predictors of expressed emotion in bipolar disorder. ( 30981096 )
2019
36
Childbirth and prevention of bipolar disorder: an opportunity for change. ( 30981755 )
2019
37
'From my point of view, my wife has recovered': A qualitative investigation of caregivers' perceptions of recovery and peer support services for people with bipolar disorder in a Chinese community. ( 30983474 )
2019
38
Suicide Risk in Comorbid Bipolar Disorder and Obsessive-Compulsive Disorder: A Systematic Review. ( 30983660 )
2019
39
Supporting Self-Management in Bipolar Disorder: Mixed-Methods Knowledge Translation Study. ( 30985287 )
2019
40
Comparison of 71 bipolar disorder pharmacotherapies for kidney disorder risk: The potential hazards of polypharmacy. ( 30986735 )
2019
41
Investigating the jumping to conclusion bias in bipolar disorder. ( 30987559 )
2019
42
Outcomes of Psychoeducation and a Text Messaging Adherence Intervention Among Individuals With Hypertension and Bipolar Disorder. ( 30991908 )
2019
43
Barriers and facilitators perceived by people with bipolar disorder for the practice of exercise: a qualitative study. ( 30994778 )
2019
44
Arnold-Chiari Type I Manifesting as Bipolar Disorder. ( 30995365 )
2019
45
The effect of adjunctive nutraceuticals in bipolar disorder: A systematic review of randomized placebo-controlled trials. ( 30999090 )
2019
46
Agitated depression in bipolar disorder. ( 31004555 )
2019
47
Obstetric complications in bipolar disorder: The role of mental health disorders in the risk of caesarean section. ( 31004826 )
2019
48
Studying the predictive factors of suicide attempts in patients with type 1 bipolar disorder. ( 31005820 )
2019
49
Retinal vascular abnormalities in schizophrenia and bipolar disorder: A window to the brain. ( 31009139 )
2019
50
Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users. ( 31014468 )
2019

Variations for Bipolar Disorder

Copy number variations for Bipolar Disorder from CNVD:

7 (show top 50) (show all 399)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13918 1 100964950 101093664 Deletion Bipolar disorder
2 13959 1 101777242 101789688 Copy number Bipolar disorder
3 14276 1 106411328 106634702 Copy number Bipolar disorder
4 15012 1 111824223 111936532 Deletion Bipolar disorder
5 15144 1 112987422 113369070 Deletion Bipolar disorder
6 15198 1 113388739 114043773 Deletion Bipolar disorder
7 15265 1 114105331 114260861 Deletion Bipolar disorder
8 15293 1 114379103 114611497 Deletion Bipolar disorder
9 15315 1 114627212 115118807 Deletion Bipolar disorder
10 17285 1 142400000 148000000 Deletion Bipolar disorder
11 17371 1 142600000 147000000 Copy number Bipolar disorder
12 17555 1 14341488 14762438 Deletion Bipolar disorder
13 18108 1 144093481 144503421 Deletion Bipolar disorder
14 21577 1 159722810 159884140 Copy number FCGR2A Bipolar disorder
15 21578 1 159722810 159884140 Copy number FCGR2C Bipolar disorder
16 21579 1 159722810 159884140 Copy number FCGR3A Bipolar disorder
17 21580 1 159722810 159884140 Copy number FCGR3B Bipolar disorder
18 21581 1 159722810 159884140 Copy number HSPA6 Bipolar disorder
19 24355 1 179082079 179207535 Deletion Bipolar disorder
20 27840 1 214001144 214182688 Deletion Bipolar disorder
21 30012 1 239069843 239226340 Deletion Bipolar disorder
22 30852 1 246404335 246667943 Deletion Bipolar disorder
23 30991 1 247034191 247138092 Deletion Bipolar disorder
24 31736 1 30336050 30952188 Deletion Bipolar disorder
25 34240 1 53925291 53984359 Copy number GLIS1 Bipolar disorder
26 35075 1 59854502 60323099 Deletion Bipolar disorder
27 35289 1 62052182 62289893 Deletion Bipolar disorder
28 35722 1 66557267 66646247 Copy number PDE4B Bipolar disorder
29 35951 1 696962 803181 Deletion Bipolar disorder
30 37047 1 84784450 84864145 Copy number CTBS Bipolar disorder
31 37048 1 84784450 84864145 Copy number SPATA1 Bipolar disorder
32 37147 1 85996510 86164671 Deletion Bipolar disorder
33 38265 10 10058972 10215130 Deletion Bipolar disorder
34 39159 10 111195021 111323778 Deletion Bipolar disorder
35 39762 10 119100000 135374737 Deletion Bipolar disorder
36 40469 10 128361479 128559816 Deletion Bipolar disorder
37 42381 10 32899498 33000799 Deletion Bipolar disorder
38 42648 10 37554667 37710375 Deletion Bipolar disorder
39 43112 10 44523027 44679489 Copy number Bipolar disorder
40 43587 10 47013328 47173619 Copy number Bipolar disorder
41 44374 10 56148428 56359760 Deletion Bipolar disorder
42 47196 10 90344868 90556337 Deletion Bipolar disorder
43 47223 10 90559662 90957411 Deletion Bipolar disorder
44 49063 11 102652001 102778728 Deletion Bipolar disorder
45 50159 11 114721884 114868905 Deletion Bipolar disorder
46 51811 11 131159857 131261275 Deletion Bipolar disorder
47 51869 11 132518807 132864395 Deletion Bipolar disorder
48 51963 11 133786141 134449982 Deletion Bipolar disorder
49 53165 11 25250128 26084796 Deletion Bipolar disorder
50 53245 11 26949271 27197653 Deletion Bipolar disorder

Expression for Bipolar Disorder

Search GEO for disease gene expression data for Bipolar Disorder.

Pathways for Bipolar Disorder

GO Terms for Bipolar Disorder

Biological processes related to Bipolar Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphate-containing compound metabolic process GO:0006796 9.37 IMPA1 IMPA2
2 response to pain GO:0048265 9.32 COMT RELN
3 dopamine metabolic process GO:0042417 9.26 COMT DRD3
4 inositol phosphate dephosphorylation GO:0046855 9.16 IMPA1 IMPA2
5 learning GO:0007612 9.13 COMT DRD3 RELN
6 inositol biosynthetic process GO:0006021 8.62 IMPA1 IMPA2

Molecular functions related to Bipolar Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inositol monophosphate 1-phosphatase activity GO:0008934 9.26 IMPA1 IMPA2
2 inositol monophosphate 3-phosphatase activity GO:0052832 9.16 IMPA1 IMPA2
3 inositol monophosphate 4-phosphatase activity GO:0052833 8.96 IMPA1 IMPA2
4 inositol monophosphate phosphatase activity GO:0052834 8.62 IMPA1 IMPA2

Sources for Bipolar Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....